BioRestorative Therapies (BRTX) announced a strategic collaboration with 203 Creates. The collaboration is designed to advance BioRestorative’s biocosmeceutical platform by establishing a differentiated brand architecture and executing a commercialization strategy. Pursuant to the agreement between 203 Creates and BioRestorative, 203 Creates is to lead the strategic development of a consumer-facing platform. 203 Creates will also be responsible to architect the underlying brand ecosystem, including brand identity, digital infrastructure, and customer journey design, to support scalable global growth.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRTX:
- BioRestorative Therapies price target lowered to $15 from $18 at Roth Capital
- BioRestorative Therapies reports blinded data from mesenchymal stem cells trial
- Is BRTX a Buy, Before Earnings?
- BioRestorative Therapies issues letter to shareholders
- BioRestorative Therapies expands global protection for ThermoStem